Drug Approval | April 20, 2023
Zydus receives final approval from USFDA for Roflumilast Tablets, 250 mcg
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Several late-stage pipeline products have the potential to address some of these unmet needs
Ministry of Ayush is leading a topic group on traditional medicine as part of Focus Group on Artificial Intelligence for Health (FG-AI4H)
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
The survey inspected ambulances operating throughout the city
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
